Germany's Boehringer Ingelheim is bowing out of the race to develop oral hepatitis C virus (HCV) therapies and has discontinued development of lead candidate faldepravir.
After a strategic review of its business, the company said it had elected to withdraw all regulatory filings for faldepravir - a protease inhibitor - because the "HCV treatment environment has significantly and rapidly evolved" in the last couple of years.
Help employers find you! Check out all the jobs and post your resume.
